Compare Amgen, Inc. (AMGN) vs Global X Cybersecurity (BUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Global X Cybersecurity — how do they compare? Amgen, Inc. trades at $363.02 (market cap $196.12B), while Global X Cybersecurity trades at $39.4. The key difference: Amgen, Inc. pays a 2.77% dividend while Global X Cybersecurity pays none, and Global X Cybersecurity is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | BUG | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $40.85 |
52-Week Low | $271.18 | $23.30 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BUG trades at $39.37, down 3.62% today, but maintains a bullish technical outlook with strong moving average signals. The cybersecurity ETF benefits from growing industry spending exceeding $300 billion in 2026, driven by AI-powered threats and corporate security budgets. However, key oscillators show neutral sentiment with RSI readings above 80 indicating potential overbought conditions.
The ETF faces valuation concerns with premium PEG ratios among top holdings, though cybersecurity remains a defensive growth theme. Risks include AI disruption to security models and competitive ETF pressure. Support at $38 and resistance at $41-43 define near-term trading ranges amid mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →
